Navigating API DMF Documentation to Avoid Customs Delays

Say an export, regulatory, or logistics lead sends out a batch of drugs, includes the Drug Master File (DMF) number with a shipment, and expects the DMF to “clear” the shipment.

Days later, the shipment is stuck in a bonded warehouse; the buyer is asking why, and no one can explain why the shipment with a confirmed DMF is stuck.

This is the most costly misunderstanding about Active Pharmaceutical Ingredient (API) import documentation.

A DMF is a regulatory submission to a drug regulatory authority.

It is not a shipment document, is never presented to a customs officer, and will never have a legal clearance at a port of entry.

What clears an API shipment is a different and more complex collection of trade and quality documents.

This document will describe in simple terms what a DMF is, the role it plays with customs, and the API shipment controls and documentation that will determine whether an API shipment is put on hold.

Now that we have set the boundaries of the problem, let’s analyze what constitutes the misconception.

The Expensive Misconception: “My DMF Will Clear the Shipment”

DMF stands for Drug Master File. A DMF is submitted to a regulator as part of a company’s confidential manufacturing documentation.

In contrast, DMFs are not customs clearance tools. Confusing the two is bound to cause serious delays that will be costly for your business.

What a Drug Master File actually is ?

A Drug Master File (DMF)^[1] describes the facilities, processes, and materials for manufacturing a substance and is submitted for regulatory confidentiality.

The FDA does not approve DMFs per se. DMFs are reviewed when referenced in a drug application, as they do not fulfill the requirements of an application.

In an actual setting, the API manufacturer is the DMF holder and sends a Letter of Authorization for a manufacturing drug application to refer to the DMF.

The confidential DMF is reviewed by the authority in regard to the drug application and not in isolation, nor in a port review.

The ASMF, or Active Substance Master File, serves as the equivalent in the EU.

The EDQM Certificate of Suitability (CEP) further offers a European Pharmacopoeia monograph compliance certificate.

They serve a similar purpose: to support a marketing authorization and not a shipment.

What a DMF is NOT ?

DMF is not provided to customs officers, does not accompany shipments, and is not part of any border control inspection.

If a DMF is deficient, the approval of all referenced drug applications will be delayed.

Customs clearance will not be affected because of a DMF deficiency.

The most expensive mistake exporters can make is to confuse the two.

DMF vs. the documents that actually clear customs:

Aspect	Drug Master File (DMF)	What Customs & the Drug Regulator Actually Check
Purpose	DMFs safeguard trade secrets for manufacturing (CMC) and support drug applications.	Determines compliance, safety, correct classification of the shipment, and applicable customs duties.
Who receives it	Drug regulator (e.g., FDA) — reviewed only if it is referenced in a drug application.	Customs authority and national drug regulatory authority (and the narcotics control authority for controlled substances, where applicable).
When it is used	During the review of a marketing authorization or drug application.	At the port of entry for every imported shipment.
Presented at the border?	No. A DMF is never presented to customs authorities.	Yes. Typical documents include the commercial invoice, Certificate of Analysis (CoA), GMP certificate, Certificate of Origin (CoO), import licence/permit, and other shipment documents as required.
Effect if deficient	May delay or prevent approval of the referencing drug application.	May result in shipment delays, detention, refusal of entry, or additional regulatory inspection at the border.

We have separated the DMF myth from its reality. We will now examine what actually occurs at the border when an API consignment is received.

What Actually Happens at the Border

It is important for any API shipment to meet the demands of three different authorities.

Clearance is determined by the quality of data and the consistency of documents, rather than by a DMF number.

Three authorities, one shipment

The three authorities involved in API clearance are the customs authority (import and export controls), the drug regulatory authority (medicinal product standards), and, where applicable, the narcotics control board.

A red flag from any one authority halts the entire shipment, and it may cost higher in detention charges .

An API submission often requires 10-15 supporting documents, compared with 4-5 for general goods.

A worked example: the US CBP → FDA flow

U.S. Customs and Border Protection (CBP) focuses on receiving entries. They provide data on FDA-regulated goods to the FDA for electronic screening.^[2]

Entries that are accurate and complete are released. Any document that is incomplete, inaccurate, or illegible is valid for human review and may result in shipment detention.

Regulatory “siblings” of DMF establishment registration and Written Confirmation are what the border verifies, not DMF.

With the real border mechanism in mind, we will examine the reasons behind stuck shipments.

Why API Shipments Actually Get Stuck

The primary reason for delays in API imports is the documentation failure.

The classification and documentation failure leads to serious delays in the shipment and increases the cost implications.

Documentation and classification failures, rather than absent regulatory dossiers, are the primary causes of delays in API and biologic imports.

The following data reveal where actual delays are incurred for exporters.

Cause of Delay	Estimated Impact on Delays	Measures to Avoid It
Inefficient or inconsistent documentation	Nearly 38% of customs and regulatory delays	Conduct a pre-shipment document review and ensure the batch numbers, product details, and quantities on the commercial invoice, Certificate of Analysis (CoA), packing list, and product labels are identical.
Incorrect HS code assignment	Nearly 22% of delays	Work with a pharmaceutical customs broker or trade compliance specialist to validate the HS code and maintain written justification for the classification.
Missing import permits or licences	Nearly, 18% of delays	Obtain all required import permits, licences, and destination-country regulatory approvals before the shipment departs.
Expired or invalid certificates	Common issue identified during regulatory verification	Keep GMP certificates, Free Sale Certificates (FSC), Safety Data Sheets (SDS), and other regulatory documents valid and up to date before shipment to avoid additional inspections or bonded storage delays.
Manufacturer registration or FEI mismatch	Can result in shipment detention or refusal of entry	Verify that the manufacturer’s registration and Facility Establishment Identifier (FEI), where applicable, are active and that the manufacturer name and address exactly match across all regulatory and shipping documents.

40% of surveyed pharmaceutical companies experienced significant customs holds on their biological materials over an 18-month period.

Clearance delays are estimated to cost US$25,000 per day,^[3] due to lost business opportunities and/or sales.

In even the most efficiently regulated markets, inconsistency between transport documents and quality documents (including discrepancies between the product name, batch identifiers, or unit numbers), coupled with misclassified customs tariff codes, most typically results in increased frequency of customs inspections and delayed clearance.

Customs holds are most frequently caused by documentation inconsistencies.

Customs tariff classification errors cause both the risk of delays and the risk of duties being incurred.

Certificate expiration is a failure governed by the calendar and is hence preventable.

Inconsistencies in registrations may not only cause delays but also result in outright refusal.

Having established the real cost of compliance failures, we will now consider where the DMF fits in to prevent this.

Where the DMF Really Fits: the Indirect but Decisive Link

The DMF does not directly clear any shipment. However, it supports the registration that legally binds the import. Its data must align with what customs inspects.

The DMF underpins the registration on which the import depends

At the moment, APIs in most markets can only be imported once the product or manufacturer is registered or authorized. And that authorization usually depends on the DMF, ASMF, or CEP.

Without filing or acceptance of the DMF, there is no registration, and therefore, the shipment can be detained or rejected.

The DMF does not cross the border, but the registration it facilitates is often a prerequisite for border crossing.

DMF data must match the documents that are checked

Here, consistency is key. The manufacturer name and address, synthesis route, and specifications in the DMF must match exactly across the Certificate of Analysis, the GMP certificate, the commercial invoice, and the import-registration record.

Customs and the drug regulator will verify all records. The address of the manufacturing site is the most common trigger for a hold if there are any discrepancies, as well as any out-of-date specifications.

An API Certificate of Analysis must contain all the tests and must include the acceptance criteria in addition to the results, all signed and dated by the Quality Unit, and must also include the original name and address of the manufacturer.

The same details that the regulators will require when assessing the registration or the DMF.

The DMF’s “regulatory siblings” are checked at the border

The foundation to which the DMF belongs does have a verification step at entry.

For APIs bound to the US, they must come from an FDA-registered facility, with the FEI number and address of the facility provided.

For APIs going to the EU, a Written Confirmation of GMP equivalence is required per Article 46b of Directive 2001/83/EC.^[4]

DMF-linked registration is a requirement, but it is not a clearance step.

Consistency of addresses and specifications across all pertinent documents is a requirement.

FEI matching is a hard requirement for APIs bound to the US.

Written Confirmation is the equivalent of a hard requirement of the EU.

With an understanding of the DMF’s real, indirect role, we can now examine the full set of documents that directly clear an API shipment.

The Complete API Import Documentation Checklist

Clearance is based on certain trade and quality documents that reference the same identifiers.

Trade and quality documents attached for clearance must contain the same identifiers and descriptions for clearance to be granted.

All documents listed must have the same batch and specification information.

Document	Purpose	Watch-out
Commercial Invoice	Lists the product details, shipment value, buyer, seller, and other commercial transaction information.	Ensure the product description, quantity, value, and HS code are consistent with the Certificate of Analysis (CoA) and other shipping documents.
Packing List	Details the contents of each package, including quantities, weights, dimensions, and packaging configuration.	Verify that the package count, weights, and quantities exactly match the physical shipment.
Bill of Lading (B/L) / Air Waybill (AWB)	Serves as the transport contract and receipt for the shipment.	Confirm that the “Shipper” is the legal owner/exporter of the goods—not merely the freight forwarder—and that all shipment details are accurate.
Certificate of Analysis (CoA)	Confirms the batch’s quality, purity, potency, specifications, and impurity profile.	Ensure the batch number matches the commercial invoice and product packaging, and that the CoA is signed and approved by Quality Control (QC).
GMP Certificate	Demonstrates that the manufacturing facility complies with Good Manufacturing Practice (GMP) requirements.	Verify that the certificate remains valid throughout customs clearance and any bonded storage period.
Certificate of Origin (CoO)	Certifies the country where the product was manufactured and supports preferential tariff claims under Free Trade Agreements (FTAs).	Required when claiming FTA benefits or reduced customs duties; ensure the origin information is accurate and properly certified.
Safety Data Sheet (SDS/MSDS)	Provides information on hazards, safe handling, storage, transport, and emergency measures.	Ensure the SDS complies with the latest Globally Harmonized System (GHS) requirements and is current.
TSE/BSE Declaration	Declares whether the product contains, or is free from, materials that may pose risks related to Transmissible Spongiform Encephalopathies (TSE) or Bovine Spongiform Encephalopathy (BSE).	Required for products containing animal-derived materials or where mandated by the importing country’s regulations.
Import Licence / Registration	Grants legal authorization to import regulated pharmaceutical products into the destination country.	Requirements vary by market (e.g., CDSCO Form 10/41 in India or an Import Drug Licence in China); obtain approval before shipment.
Pharmacopoeial / Specification Reference	Specifies the applicable quality standard (e.g., USP, BP, EP, IP) for the product.	Ensure the pharmacopoeial standard matches the product registration, purchase order, and Certificate of Analysis.

Examining how requirements change from market to market is all the more important now that we have the universal checklist.

Market-by-Market Import Requirements

API import regulations are local and not global. Each key market has its own registration instrument and risks pertaining to timelines.

Market	Key Import Instruments	Who Checks / Notes
United States (FDA + CBP)	FDA Establishment Registration (FEI), Prior Notice (where applicable), Product Listing, and other FDA import requirements.	The U.S. Food and Drug Administration (FDA) and U.S. Customs and Border Protection (CBP) verify that products originate from a properly registered facility. Materials from an unregistered establishment may be refused entry regardless of product quality.
European Union	Written Confirmation (GMP equivalence under Directive 2001/83/EC, Article 46b), Manufacturing and Import Authorisation (MIA), Qualified Person (QP) Batch Release, and ASMF/CEP reference where applicable.	The importer’s Qualified Person (QP) certifies that each batch complies with EU GMP requirements before it can be released to the market.
China (NMPA)	Import Drug License (typically requiring 12–18 months for approval), Good Importation Practice documentation, and National Institutes for Food and Drug Control (NIFDC) arrival testing.	The National Medical Products Administration (NMPA) and NIFDC perform mandatory arrival testing for many imported pharmaceutical products, which can extend release timelines by several weeks.
India (CDSCO)	Registration Certificate (Form 41), Import Licence (Form 10), and Form 29 where applicable for scheduled APIs or testing purposes.	The Central Drugs Standard Control Organization (CDSCO) verifies that all required import permits and registrations are in place. These approvals should be obtained before the shipment departs from the country of origin.

In the US, you need an active registration of the facility, not a lot of paperwork.

In the EU, a human has to sign off on each batch (QP certification).

China’s import licenses (12-18 months) must be factored in well in advance, as you may not be able to ship goods.

India requires that all permits be completed in advance, not upon arrival.

We have now addressed the specific regulations in each market. Let us focus on the operational playbook that maintains uniform documentation for each of them.

The Documentation-Consistency Playbook

To ensure uniformity with every document, formally stopping a shipment or stopping a preservation system cannot simply be completed with documentation. There must be a process. Consistent discipline on every document stops a shipment.

API import documentation can be seen as a cohesive and connected system, built once and reused.

Using a broker who specializes in pharma and understands the cross-referencing of the drug authority clears API shipments much more reliably than using a freight forwarder.

Now that we have the system established, let’s examine the disciplines of operations.

How Actiza’s Documentation Discipline Keeps Shipments Moving

Keeping your regulatory documentation current and having documentation for quality assurance that is easy to trace makes compliance a competitive advantage, rather than a requirement you must defend against.

Manufacturers that have up-to-date WHO-GMP status, DMFs and CEPs, and that issue consistently traceable Certificates of Analysis, provide importers with exactly what the cross-border checks require: certificates that match identifiers and a verifiable registration.

This level of compliance and documentation makes significant delays in your process a competitive advantage. For certifications and quality systems for manufacturers, visit Actiza’s certification page.

For product-specific information, visit the APIs page.

DMF, ASMF, and CEP support can be found on the regulatory page. To talk about export documentation for a specific shipment, visit the API export contact page.

Now that we have gone through the entire system, let’s look at the most common questions asked by exporters.

FAQ Section

Conclusion

Drug Master Files hold significant benefits for API manufacturers, but shipments cannot be cleared through DMFs.

The main factor in clearing customs is the accuracy, authenticity, and thoroughness of the trade and customs documents presented at the border.

This relies on having the proper customs approval and can be aided through a DMF.

All of the trade documents must utilize the same identifiers and be signed and stamped using the same certifying officer.

With this, problems with customs clearance become less common. Document consistency and accuracy are critical for avoiding unexpected delays and costs in the supply chain.

If your team needs assistance aligning DMF, ASMF, CEP submissions, or other filings with your import documentation, Actiza’s regulatory documentation team can help.

Please contact us through our API export contact page.